Royal Bank Of Canada Aveo Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.48 - $14.97 $8,895 - $15,703	-1,049 Reduced 92.91%	80 $1,000
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $2,174 - $2,868	329 Added 41.13%	1,129 $10,000
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $14,725 - $19,815	-2,876 Reduced 78.24%	800 $5,000
Q2 2021 Aug 16, 2021	BUY	$6.21 - $7.45 $22,827 - $27,386	3,676 New	3,676 $24,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.